Provided by Tiger Trade Technology Pte. Ltd.

Urogen Pharma Ltd.

43.09
-0.5300-1.22%
Post-market: 43.090.0001+0.00%16:30 EDT
Volume:748.99K
Turnover:31.98M
Market Cap:2.10B
PE:-21.87
High:44.86
Open:43.17
Low:42.00
Close:43.62
52wk High:50.81
52wk Low:15.86
Shares:48.68M
Float Shares:43.35M
Volume Ratio:1.18
T/O Rate:1.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9700
EPS(LYR):-3.1901
ROE:-1481.26%
ROA:-18.06%
PB:-15.84
PE(LYR):-13.51

Loading ...

Nov 19, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 06, 2025

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Nov 06, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 06, 2025

Major Issues Report

Form 8-K - Current report
Sep 09, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Sep 09, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 27, 2025

Major Issues Report

Form 8-K - Current report
Aug 07, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 07, 2025

Major Issues Report

Form 8-K - Current report
Jul 29, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jul 29, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jul 03, 2025

Major Issues Report

Form 8-K - Current report
Jun 13, 2025

Major Issues Report

Form 8-K - Current report
Jun 10, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 12, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 12, 2025

Major Issues Report

Form 8-K - Current report
May 01, 2025

[Rev.]Annual Report

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Mar 10, 2025

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 10, 2025

Major Issues Report

Form 8-K - Current report
Feb 20, 2025

Major Issues Report

Form 8-K - Current report